Received: 9 January 2022
Accepted: 4 May 2022
First Online: 23 May 2022
Change Date: 26 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13045-022-01321-4
: Murine studies were conducted after IACUC approved protocol.
: Granted by authors.
: A.V. has received research funding from Prelude, BMS, GSK, Incyte, Medpacto, Curis and Eli Lilly, is a scientific advisor for Stelexis, Novartis, Acceleron and Celgene, receives honoraria from Stelexis and Janssen and holds equity in Stelexis and Throws Exception. RM is an employee of Curis.